Home › Compare › TBGNF vs GBDC

TBGNF vs GBDC: Dividend Comparison 2026

TBGNF yields 1176.47% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBGNF wins by $78814174.35M in total portfolio value
10 years
TBGNF
TBGNF
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full TBGNF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — TBGNF vs GBDC

📍 TBGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBGNFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBGNF + GBDC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TBGNF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBGNF
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, TBGNF beats the other by $57,395,132,082,001.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBGNF + GBDC for your $10,000?

TBGNF: 50%GBDC: 50%
100% GBDC50/50100% TBGNF
Portfolio after 10yr
$39407108.03M
Annual income
$33,761,858,851,911.11/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

TBGNF
No analyst data
Altman Z
-23.0
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBGNF buys
0
GBDC buys
0
No recent congressional trades found for TBGNF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBGNFGBDC
Forward yield1176.47% ✓11.86%
Annual dividend / share$2.00 ✓$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1% ✓
Portfolio after 10y$78814195.20M ✓$20.85M
Annual income after 10y$67,523,701,253,088.38 ✓$16,450,733.83
Total dividends collected$77969765.27M ✓$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TBGNF vs GBDC ($10,000, DRIP)

YearTBGNF PortfolioTBGNF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$128,347$117,647.06$12,492$1,791.70+$115.9K → TBGNF
2$1,548,514$1,411,182.61$16,527$3,160.58+$1.53M → TBGNF
3$17,569,052$15,912,142.01$23,588$5,904.90+$17.55M → TBGNF
4$187,523,354$168,724,468.35$37,141$11,901.65+$187.49M → TBGNF
5$1,883,716,681$1,683,066,692.55$66,205$26,463.38+$1883.65M → TBGNF
6$17,816,329,317$15,800,752,468.33$137,452$66,612.65+$17816.19M → TBGNF
7$158,731,384,105$139,667,911,735.60$342,372$195,298.53+$158731.04M → TBGNF
8$1,332,782,916,056$1,162,940,335,063.89$1,053,292$686,954.33+$1332781.86M → TBGNF
9$10,551,863,503,163$9,125,785,782,982.70$4,111,439$2,984,416.95+$10551859.39M → TBGNF
10$78,814,195,201,473$67,523,701,253,088.38$20,849,974$16,450,733.83+$78814174.35M → TBGNF

TBGNF vs GBDC: Complete Analysis 2026

TBGNF — Stock

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Full TBGNF Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this TBGNF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBGNF vs SCHDTBGNF vs JEPITBGNF vs OTBGNF vs KOTBGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.